<html>

<head>
<meta name="GENERATOR" content="Microsoft FrontPage 6.0">
<meta name="ProgId" content="FrontPage.Editor.Document">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<title>中國時報 2008</title>
<meta name="Microsoft Theme" content="none, default">
</head>

<body>

<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci1_1.js">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci1_2.js">
</script>
<script language="JavaScript" src="http://gkplus.contentinside.net/CIGKP2.aspx?wid=1&kw0=%u6CBB%u7642&kw1=%u816B%u7624&kw2=%u53F0%u5927&adc=3&adt=3">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci1_3.js">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/pat/gkp03.js">
</script>
<link href="http://inserter.contentinside.net/images/style0701.css" type="text/css" rel="stylesheet">
<script language="JavaScript" src="http://inserter.contentinside.net/hot/HotKeyword.js">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci1_4.js">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci1_5.js">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci1_6.js">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci1_7.js">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-Hm/0,4575,,00.js">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CHGroup/0,4581,,00.js">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH05/0,4799,110501,00.html">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH01/0,4577,110502,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH04/0,4580,110507,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH04/0,4580,110508,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH01/0,4577,110503,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH01/0,4577,110504,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH01/0,4577,110505,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH04/0,4580,110506,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH02/0,4578,110509,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH06/0,4834,110511,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH04/0,4580,110512,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH01/0,4577,110514,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH02/0,4578,110517,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH04/0,4580,110518,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH01/0,4577,110519,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH02/0,4578,110513,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH03/0,4579,11051301,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH03/0,4579,11051302,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2007-GuideBar-HM-CH03/0,4579,11051303,00.shtml">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2008-GuideBar-Hm2/0,4824,,00.js">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2008-GuideBar-HM2-CHGroup/0,4828,,00.js">
</script>
<script src="http://news.chinatimes.com/2007Cti/2007Cti-Common/Inc/2007-GuideBar-HM/2008-GuideBar-HM2-Edit/0,4825,market+DMArr01,00.shtml">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci1_8.js">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci1_9.js">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci1_10.js">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci1_11.js">
</script>
<script language="JavaScript" src="http://inserter.contentinside.net/ci/ctnews4ci2_1.js">
</script>
<span class="txt15">
<p style="line-height: 150%"><span class="txt13">中國時報 2008.04.27　 </span><br>
<span class="txt24RB">
<!--title begin-->多發性骨髓瘤 「萬科」療效佳<!--title end--></span><br>
<span class="txt13">
<!--authorname begin-->黃天如／台北報導<!--authorname end--></span> </p>
<p style="line-height: 150%">多發性骨髓瘤目前為國內排名第三的血液惡性<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u816B%u7624" target="_blank" style="text-decoration: none"><font color="#000000">腫瘤</font></a>，但該症發生率較廿年前<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u6210%u9577" target="_blank" style="text-decoration: none"><font color="#000000">成長</font></a>了四倍，是<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u53F0%u7063" target="_blank" style="text-decoration: none"><font color="#000000">台灣</font></a>發生率上升最快的血液<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u816B%u7624" target="_blank" style="text-decoration: none"><font color="#000000">腫瘤</font></a>。根據<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u570B%u5916" target="_blank" style="text-decoration: none"><font color="#000000">國外</font></a>最新臨床研究，多發性骨髓瘤<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u6A19%u9776" target="_blank" style="text-decoration: none"><font color="#000000">標靶</font></a>藥物「萬科」（Velcade）用於第一線<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u6CBB%u7642" target="_blank" style="text-decoration: none"><font color="#000000">治療</font></a>，腫瘤完全消失的比率近三成，效果不錯。<font color="#FF0000">(<span lang="zh-tw">之所以會成長四倍，就是民眾喜歡吃西藥跟維他命造成的惡果。</span>)</font></p>
<p style="line-height: 150%">　二○○八年亞太區血液及骨髓移植大會昨天在<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u53F0%u5317" target="_blank" style="text-decoration: none"><font color="#000000">台北</font></a>舉行，會中特邀請美國Winship癌症中心副教授Lonial與會，與國內專家<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u4EA4%u6D41" target="_blank" style="text-decoration: none"><font color="#000000">交流</font></a>。 
</p>
<p style="line-height: 150%">　<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u53F0%u5927" target="_blank" style="text-decoration: none"><font color="#000000">台大</font></a>血液腫瘤科主治<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u91AB%u5E2B" target="_blank" style="text-decoration: none"><font color="#000000">醫師</font></a>黃聖懿表示，國內雖也核准<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u6A19%u9776" target="_blank" style="text-decoration: none"><font color="#000000">標靶</font></a>藥物「萬科」適應症為多發性骨髓瘤，<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u5065%u4FDD" target="_blank" style="text-decoration: none"><font color="#000000">健保</font></a>也於去年六月列入給付範圍，但僅限經兩種<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u5316%u7642" target="_blank" style="text-decoration: none"><font color="#000000">化療</font></a>藥物<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u6CBB%u7642" target="_blank" style="text-decoration: none"><font color="#000000">治療</font></a>無效之患者。<font color="#FF0000">(其副作用為何?從未說清楚。)
</font> 
</p>
<p style="line-height: 150%">　<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u53F0%u5927" target="_blank" style="text-decoration: none"><font color="#000000">台大</font></a>以「萬科」用於復發且頑固性骨髓瘤患者的經驗，其「完全緩解」（腫瘤消失，ＣＲ）加上「部分緩解」（ＰＲ）的比率也有三成，治療效果同樣較<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u50B3%u7D71" target="_blank" style="text-decoration: none"><font color="#000000">傳統</font></a><a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u5316%u7642" target="_blank" style="text-decoration: none"><font color="#000000">化療</font></a>優異許多。<font color="#FF0000">(如果這數據是真的，治療後又沒有副作用，當然很好，可是可能嗎?)
</font> 
</p>
<p style="line-height: 150%">　多發性骨髓瘤患者平均年齡偏高，且發現時常太晚，治療十分棘手。<font color="#FF0000">(上段剛說完治療效果很好，這段立刻又說很棘手，不知在玩甚麼把戲。)
</font> </p>
<p style="line-height: 150%">　一名五十四歲的貨車司機，就因輕忽右腿酸痛問題，只買<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u63D0%u795E" target="_blank" style="text-decoration: none"><font color="#000000">提神</font></a>飲料及到國術館推拿，後來搬貨到二樓，右大腿骨竟應聲斷成兩截，才被診斷為多發性骨髓瘤末期。 
</p>
<p style="line-height: 150%">　因為發現得太晚，這位貨車司機，甚至連接受高劑量化學治療合併自體造血<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u5E79%u7D30%u80DE" target="_blank" style="text-decoration: none"><font color="#000000">幹細胞</font></a>移植的<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u6A5F%u6703" target="_blank" style="text-decoration: none"><font color="#000000">機會</font></a>都沒有，發病不到半年就過世了。<font color="#FF0000">(這裡說明台灣的西醫師的態度是寧可眼睜睜的看著病人死，也絕對不勸病人去看中醫。只活半年是因為死於西醫的治療上，不是真正病死的。)
</font> 
</p>
<p style="line-height: 150%">
　黃聖懿強調，多發性骨髓瘤是一種發生在骨髓血液中的淋巴腫瘤，跟骨骼沒有關係；患者常出現的症狀還有貧血、蛋白尿、腎功能低下等，特異性都不明顯，若警覺性不夠，極易延誤就醫。<font color="#FF0000">(西醫學都是只知道片段的醫學，中醫認為腎主骨，此病會出現腎功能低下，就是與腎有關。)
</font> 
</p>
<p style="line-height: 150%">　他說，根據台大<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u91AB%u9662" target="_blank" style="text-decoration: none"><font color="#000000">醫院</font></a>一九九六年至二○○五年收治之五二六名多發性骨髓瘤患者為例，近六成都是第三期（最末期）患者。 
</p>
<p style="line-height: 150%">而其致死率也極高，國內統計約八成患者最後會死於該症，平均存活期也只有三到四年。<font color="#FF0000">(台大醫院既然知道死亡率極高，為何不找中醫幫忙呢?)
</font> </p>
<p style="line-height: 150%">　「萬科」的藥價相當驚人，目前國內每劑<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u5065%u4FDD" target="_blank" style="text-decoration: none"><font color="#000000">健保</font></a>給付價四萬一五一二元，患者每周須注射兩劑，一個療程用藥兩周、<a class="cidkligk" title="搜尋這個關鍵字的相關內容" href="http://www.contentinside.net/redirkey.aspx?wid=1&kw=%u4F11%u606F" target="_blank" style="text-decoration: none"><font color="#000000">休息</font></a>一周，又完整治療須連續進行四到八個療程，費用高達六十六萬至一三二萬多元。<font color="#FF0000">(越貴台灣人就認為越有效，真正可以治療這種多發性骨髓瘤的是中藥，絕對不是西藥。)</font></p>
</span>

<p align="center"><font color="#FF0000"><b>評論</b></font></p>
<p align="left" style="line-height: 150%"> 
從頭到尾這篇報導中，就是不提及副作用為何? 
像西藥抗乳癌藥物泰莫西芬，其副作用就是卵巢癌，也就是說病人不吃西藥時，只是單純乳癌而已，如果吃西藥來抗乳癌，結果就是乳癌還在，但是又增加另外一個敵人，就是卵巢癌，如果這種西藥萬科，其副作用就是容易致癌，那就算吃這種藥物<span class="txt15">，骨髓瘤好了，但是病人卻死於另一種癌症，請問有用嗎?</span></p>

</body>

</html>
